Core Viewpoint - The article emphasizes the transformative opportunities in the innovative pharmaceutical sector, predicting that 2025 will mark a significant year for revenue growth, profit breakthroughs, and valuation increases in the industry [4][5]. Group 1: Innovative Drug Investment Outlook - The innovative drug sector is entering a "three-dimensional screening era" characterized by major disease categories, clinical data validation, and global competition [4]. - 2025 is anticipated to be the starting point for collective revenue growth among innovative drug companies, with 80% of A-share and Hong Kong-listed innovative drug firms expected to see revenue increases following 2024's medical insurance negotiations [5]. - The period from 2025 to 2028 is projected to be crucial for many Chinese innovative drug companies to enter profitability, contrasting with previous years where only a few companies achieved profits [5]. Group 2: Key Investment Areas in Innovative Drugs - Focus areas for investment include: 1. Bispecific antibodies, with the first approved product in China and several in late-stage clinical trials [8]. 2. Antibody-drug conjugates (ADCs), where domestic companies lead in the development of the next generation of ADCs [8]. 3. Targeted therapies, with the global oncology drug market exceeding $150 billion, and a significant share expected to come from domestic small molecules by 2030 [8]. 4. Autoimmune diseases, driven by environmental factors and improved insurance coverage, with a focus on kidney disease drugs showing substantial growth [8]. Group 3: Investment Strategy and Methodology - The investment strategy in the pharmaceutical sector is based on three selection criteria: 1. Focus on large market spaces, such as oncology and metabolic diseases, to mitigate R&D risks [10]. 2. Prefer clear competitive landscapes, such as orphan drugs, with minimal competition expected in the next three years [10]. 3. Target products with optimal clinical data, avoiding those that do not meet top-tier standards [10]. Group 4: Insights from Fund Managers - Fund manager Wu Qingyu emphasizes the importance of absolute return thinking, focusing on high-growth sectors while maintaining valuation discipline [11][12]. - Wu's investment approach combines top-down and bottom-up strategies, selecting high-growth industries and then identifying companies with superior growth rates and matching valuations [15]. - The focus on concentrated holdings is driven by strong research conclusions, aiming for higher alpha returns through precise stock selection [17]. Group 5: Future Investment Directions - Wu Qingyu identifies three key sectors for future investment: 1. AI computing power, driven by increased domestic demand for servers and capital investments from companies like ByteDance [19]. 2. Investment opportunities in "AI new hardware" arising from the integration of AI models with downstream hardware [19]. 3. The automotive sector's trend towards smart technology, with certain domestic manufacturers expected to gain market share [19].

去年以来，优秀主动权益基金经理走出业绩调整期，产品净值不仅修复回撤，更开启上升趋势，部分基 金经理的基金净值曲线在今年站上历史高点。信达澳亚基金基金经理吴清宇便是其中代表，投资生涯起 步于保险资管的吴清宇，和很多险资背景的基金经理类似，秉持"绝对收益思维"。他通过产业前瞻与动 态估值管理获取长期绝对回报，在管信澳景气优选、信澳优势产业等基金近一年业绩均位居同类前列。 近期，吴清宇在接受证券时报记者专访时表示，通过产业前瞻锁定高成长赛道，以合理估值深挖优质个 股，高频扫描市场动态，始终保持组合高性价比，致力于为投资者创造长期价值。 绝对收益思维 构筑投资根基 吴清宇拥有北京大学电子学学士、经济学硕士以及香港大学金融学硕士学位，具备工科和金融复合背 景。2011年7月起，他历任融通基金、德邦证券行业研究员。他的投资生涯起步于保险资管领域，2016 年在中国人保资管担任专户投资经理，后进入公募基金行业担任基金经理，2020年加入信达澳亚基金。 在公募基金行业从业多年，吴清宇践行"绝对收益思维"。他认为，投资获利不仅需要资产优质，还需要 足够便宜。通过选择便宜的优质资产，自然能获得良好回报。 这一理念与GARP策略（ ...